Table 3.
Content of acetaminophen and its metabolites in plasma and urine ( ± SD)
| Hepatocellular carcinoma (n = 23) | Cirrhosis (n = 21) | Healthy participants (n = 18) | |
|---|---|---|---|
| Plasma‐free acetaminophen (μg/mL) | 3.75 ± 0.88 | 4.18 ± 1.16 | 4.07 ± 0.81 |
| Plasma‐conjugated acetaminophen (μg/mL) | 4.93 ± 2.38 | 4.20 ± 2.88 | 4.58 ± 2.02 |
| Plasma total acetaminophen (μg/mL) | 8.68 ± 2.56 | 8.38 ± 3.28 | 8.65 ± 2.19 |
| Urine acetaminophen (%) | 3.81 ± 1.36** | 7.42 ± 1.60* | 4.86 ± 0.62 |
| Urine glucuronide acetaminophen (%) | 17.12 ± 3.37*,** | 54.04 ± 6.93 | 53.56 ± 13.78 |
| Urine sulfate acetaminophen (%) | 79.07 ± 3.68*,** | 38.54 ± 7.14 | 41.58 ± 13.64 |
| Ratio of glucuronide acetaminophen: sulfate acetaminophen | 0.22 ± 0.04*,** | 1.46 ± 0.52 | 1.55 ± 1.01 |
| Recovery of urine total acetaminophen | 69.19 ± 18.51 | 65.24 ± 22.43 | 72.46 ± 23.83 |
*P < 0.01 vs healthy patients; **P < 0.01 vs cirrhosis patients.